Bristol-Myers Squibb (BMS) and Catalent have announced that Catalent has agreed to purchase BMS’ oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.

The 19,300-square-meter Anagni plant has served as one of the primary launch facilities for BMS for new medicines for cancer and cardiovascular disease. The facility manufactures and packages cardiovascular, neuroleptics, anticancer, metabolic and anti-inflammatory medicines as well as non-penicillin-based antibiotics, antivirals, analgesics, injectables and biologics. Upon closing, Catalent will continue to manufacture BMS’ current production portfolio at the site.

The facility will provide Catalent biologics with oral solid dose manufacturing and packaging and advanced sterile drug product fill–finish and packaging capacity in Europe to complement its existing sterile fill–finish capabilities in Belgium and its drug-substance, analytical, and fill–finish capabilities in North America.

The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals, the information and consultation procedure with the unions, and the satisfaction of certain other customary closing conditions.

Source: Catalent